Commons health committee backs sugar tax

MPs support government curbs on price discounts on unhealthy food

Hands finds little relief for care homes

Terra Firma chief does not consider major restructuring necessary

Minimum wage impact slows healthcare M&A

Fears over the living wage were the biggest barrier to investing

Science: The clone factory

With new plans for cloned cattle is China’s taboo-busting biotech sector widening the ethical gap with the west?

Pfizer’s Read looks to count on Allergan

Deal would be crowning achievement of career forged in accounting

Cloned cows cause beef on climate change

UN estimates global meat industry belches out 14.5% of global greenhouse gas emissions

GSK picks tough China path after scandal

New rules to tackle corrupt practices leave drugmaker at a commercial disadvantage, say industry peers

GSK confident of China renaissance

Drugmaker looks to repair reputation shattered by corruption scandal

WEALTH MAGAZINE West Hall Care home Surrey, part of a trend for care catering to wealthy pensioners. Pictured Residents taking part in Tai Chi. Credit: David Parry/ FT
©David Parry

Fears rise for care homes

Chancellor fails to deliver substantial rise in funding

Ingram Pinn illustration, Pfizer
©Ingram Pinn

Big Pharma is addicted to an illusion

Paying high prices for proven drugs and taking a hit to the balance sheet does not avoid the bill

‘Excess winter deaths’ stir NHS fears

Last year’s UK figures highest since beginning of the millennium

Nigeria on track to be polio-free by 2017

Two hundred thousand volunteers immunise 45m children

Political risk clouds Pfizer-Allergan deal

Investors and analysts see the transaction as vulnerable to a change in ‘tax inversion’ law

Corporate tax: The $240bn black hole

Pfizer-Allergan merger set to increase calls for the US to close inversion loopholes, and for the OECD to get tough on avoidance

Obama should close Pfizer’s tax loophole

Drug company’s tax inversion shows poor corporate citizenship

A false alarm on red meat and cancer

Two large trials have tested for evidence and the WHO ignored both of them, writes Gordon Guyatt

How to avoid ‘retirement shock’

Plan carefully to avoid psychological strain of end to working life

Pfizer seeks US support for Allergan deal

Drugmaker tries to fend off opposition as politicians line up to attack Irish takeover

Four Seasons losses widen as costs rise

UK’s biggest care home operator says it cash for “medium-term”

Pfizer bulks up in era of slimming down

‘Pfizergan’ could eventually be split but not until at least 2018


More FT Twitter accounts